Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.

ABSTRACT:

Purpose

Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering multiTAA T cells targeting the tumor-expressed antigens, Survivin, NY-ESO-1, MAGE-A4, SSX2, and PRAME, to patients with relapsed/refractory/metastatic BC.

Materials and methods

MultiTAA T-cell products were generated from the peripheral blood of heavily pre-treated patients with metastatic or locally recurrent unresectable BC of all subtypes and infused at a fixed dose level of 2 × 10⁷/m². Patients received two infusions of cells 4 weeks apart and safe

SUBMITTER: Hoyos V 

PROVIDER: S-EPMC9290161 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature